Drug Trial Radar · NCT01860482
The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD
Last checked: Nov 20, 2026Latest source record: Sep 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Apr 2013
Primary completion
May 2015
Study completion May 2015
Sponsor
- Lead sponsor
- Chong Kun Dang PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- May 22, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.
Conditions
- Reflux Esophagitis
Interventions
Newrabell® Tablet 10mgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to onset of first 1Day Heartburn free, DaysTime frame: up to 8 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Chonnam National University Hospital
Gwangju, Donggu, Jebongro, South Korea
Chonnam National University Hwasun Hospital
Gwangju, Hwasun-eup,Hwasun-gun, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.